Health Systems Partners Panel at RESI Boston, September 6th, 2018

By Claire Jeong, Senior Research Analyst, LSN

claireAn increasing number of health systems are seeking to form strategic partnerships with early-stage companies that could serve as a meaningful solution for the various complexities within the healthcare system. These strategic partnerships would be tremendously valuable for a start-up entrepreneur, as the value-add that health system organizations can provide are not limited to direct equity investment. Through working with large health/hospital systems, companies gain access to various channels, abundant resources, and relationships with key clinicians or medical professionals that they otherwise may not be able to manage on their own.

So how can companies seek to access these channels, and what exactly does each organization have to offer? At RESI Boston on September 6th, we had the tremendous pleasure of inviting 5 panelists from health systems – all with a unique approach to working with early-stage innovations – to speak about their work and perspectives in fostering novel innovations that can impact the course of healthcare.

For those who missed this session, we have prepared a shortened video of the panel that highlights the main discussion points. If you are someone seeking to leverage relationships with health systems, I hope you find these insights helpful!

Our panelists included:

  • Brent Stackhouse, Vice President, Mount Sinai Ventures, Inc. (Moderator)
  • Richard Gordon, Director, Inova Strategic Investments
  • Anne Wellington, Managing Director, Cedars-Sinai Accelerator
  • Eric Feinstein, Investment Director, Northwell Ventures
  • Sarah Lindenauer, Product & Portfolio Manager, Boston Children’s Hospital IDHA

A brief profile for each organization:

Mount Sinai Ventures – Mount Sinai Health System is a hospital system in New York. Their venture arm, Mount Sinai Ventures, started in 2008 with the goal of investing in care delivery (urgent care, ambulatory services). About 4 years ago, their interests diversified into medical devices and digital health. The group invests $500K in average, as little as $50K and as much as $1.5M, with about 20 investments in the portfolio. Mount Sinai Ventures is constantly trying to find ways to partner with other individuals within the health system and build or create value for portfolio companies.

Inova Personalized Health Accelerator (Inova Strategic Investments) – Inova is a hospital system in the Northern VA area, and IPHA is their accelerator arm. Inova has historically made several strategic investments, generally to drive innovation into the hospital system. They have a $150M balance sheet commitment which they are aiming to allocate over a 24-month period. The firm invests in multiple ways – they are a fund of funds and have a LP position in several like-minded funds. With regards to their seed portfolio, the average investment size is around $500K-1M. IPHA has a fixed price, fixed equity structure ($75K for 10% equity stake, with potential for $250K investment in follow-on).

The Cedars-Sinai Accelerator – Cedars-Sinai Accelerator is the accelerator program of Cedars-Sinai Medical Center, through which they invest $120K in participating companies. This has been in partnership with Techstars in the past but they will soon be operating independently. In partnership with MemorialCare, Cedars-Sinai is also involved with seeking investments through Summation Health Ventures that focus on Series A/B investments in the $5-10M range.

Northwell Ventures – Northwell Ventures is a venture equity practice at Northwell Health. Northwell is the largest health system in NY state, with 23 hospitals in the network. They are about to close on their 16th investment. Their investment areas of interest ranges from medical devices through digital health and other services. They also participate in corporate carveouts, where they put seed capital into non-core assets within the system and partner with external capital in efforts for revenue cycle management.

Boston Children’s Hospital IDHA – Based in Boston, MA, Boston Children’s Hospital’s Innovation & Digital Health Accelerator (IDHA) is Boston Children’s Hospital’s accelerator arm and is supported by a 50-person team. Of this team, about 25 people are technologists, software developers, etc. and is very deep on team/resources. While there is no investment arm, IDHA provides very high-touch, customized support, and software development resources that provides strategic value beyond capital.

Hot Investor Mandate: Specialized VC Arm of a Chinese Holding Company Invests Broadly Across Therapeutics, Devices, Diagnostics, Digital Health, Including Orphan Drugs

A specialized USA venture capital firm under a large Chinese holding company has headquarters in Shanghai, China and an additional virtual office in the USA. The firm is actively seeking investment opportunities from early-stage to pre-IPO rounds.  The average size of investment is around $5M. The firm has invested in 17 US & Canada companies since 2016.

The firm is a flexible and opportunistic investor that is currently considering Therapeutics, Medical Devices, and Diagnostics. The firm will also consider orphan drugs and digital health companies. The firm is open to all kinds of sectors. The firm is open to medical devices with all FDA regulatory pathways, including 510k and PMA.  The firm is open to medical devices and therapeutics in any stage of development. However, the firm will invest in private companies only.

The firm has no specific requests on the management team. The firm can act as the lead investor or co-investor depends on different cases, and the firm prefers to have a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: USA Investment Firm Seeks Opportunities in Pre-Revenue, Early-Stage Life Science Technologies with Strong IP

An investment firm based in the USA has a newly established venture capital strategy, which has a specific focus in early-stage, pre-revenue biotech companies. The firm’s initial investment is usually around $500K, but the firm has invested as low as $250K and as high as $2-3M. At present, the firm is primarily looking for USA-based opportunities with a focus on the Midwest and East Coast regions.

The firm invests broadly across early-stage therapeutics, medical devices, and diagnostics. The firm is most interested in technologies with strong intellectual property. The firm is open to investing in all classes of medical devices including 510k and PMA. The firm works closely with a group of scientists who covers a wide range of expertise including cancer diagnostics, immunotherapy, diseases of the ear and eye, etc. The firm is not interested in healthcare analytics companies.

The firm is flexible and is open to working with all different kinds of management teams, though experience and a successful track record is a plus. The firm has both led and co-invested in financing rounds and seeks board representation most of the time.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: VC Firm with USA and Europe Offices Invests in Therapeutics, Medical Device, and Diagnostic Companies with $585M Fund

A venture capital firm with multiple offices in the USA and Europe is currently investing from the firm’s newest $585 million venture fund. The firm is open to investment opportunities globally.

The firm is currently interested in novel concepts and platforms across the life sciences. The firm invests in therapeutics, devices and diagnostics, and has a lesser interest in technology-led companies in the healthcare IT space (the firm is not interested in service-based/SaaS healthcare IT businesses). The firm prefers early stage opportunities; in therapeutics, the firm focuses on pre-IND technologies.

While the firm invests across many areas, one focus at present is immunology assets that aim to treat infectious diseases (viral and bacterial), with a focus on immune priming or changing the immune system. Any immunological therapeutic modality is of interest, including vaccines. The firm is interested in reviewing immunology assets at any stage of development.

The firm only invests in privately held companies that have not previously raised a Series A round or a significant seed round. The firm is a highly hands-on, active investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: VC Firm Seeks to Invest in Novel, Digital Healthcare Technologies with Strong Incorporation of Data, Including AI, Precision Medicine, etc.

A venture capital firm founded in 2012 with $300M AUM is currently investing from its third fund. The firm focuses on early-stage investments from Seed to Series A, and initial size of investment can range from $500K to up to $3M. The firm reserves a significant part of the fund as follow-on investment. With the current fund, the firm seeks to invest in a total of 6-8 companies, with a preference for companies that are within proximity to their office in the Bay area.

The firm is interested in technologies that incorporate mobility and data. In terms of life sciences and healthcare, this includes digital health, AI and big data in discovery, precision medicine, etc. The firm has made several investments in digital health companies – examples include a mobile coaching app that promotes smarter decisions and better outcomes, a digital health platform for chronic disease management, etc.

The firm looks for driven management teams – relevant industry experience is a definite plus, but not an absolute requirement. The firm works closely with portfolio companies, providing companies with the needed resources and expertise to achieve scalability. The firm prefers to act as the lead investor, typically taking a board seat in such cases.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

RESI Boston 2018 Innovation Challenge – Check Out the Winners

By Nono Hu, Director of Marketing, LSN

On September 6th, more than 700 scientist-entrepreneurs and investors entered the exhibition hall at Boston Marriott Copley Place to participate in the RESI conference. They were greeted by 30 Innovation Challenge finalists across therapeutics, medical device, diagnostics, and digital health sectors. The 30 companies, evaluated by LSN’s expert system and scientific & commercial review team, competed directly on merits of innovation and commercial viability. We wish all our finalists the best in bringing their products forward toward commercialization, but there could only be 3 top prize winners.

First Prize: Heartlander Surgical

The HeartLander System’s new approach to debilitating ventricular (heart) conditions comprises low cost disposables and an inexpensive, reusable controller: 1. Disposable sensor array placed on the outside of the torso 2. Disposable, tethered, percutaneously delivered, epicardial walker with multimodal sensing (e.g., Doppler ultrasound for avoiding coronaries) and insertable needle for saline-enhanced radiofrequency ablation (creates small, precise lesions) or for delivering therapy into the myocardium3. Control System that integrates sensor data, maps the heart defect, actuates the walker, plans actions, and provides a visualization display screen and control interface for the physician. Our first clinical focus (NIH-funded through animal PoC) is ventricular tachycardia, but the technology platform can be used for myocardial regeneration therapies, ventricular reshaping, and biventricular pacing.

Dennis Ford, Founder & CEO, Life Science Nation | Rick Berenson, CEO, Heartlander Surgical | Dwight Meglan, CTO and Founder, Heartlander Surgical | Lucy Parkinson, VP of Investor Research, LSN

Second Prize: BrainStem Biometrics

At BrainStem Biometrics we’re pioneering a new multi-billion medical device category to measure the most important part of the brain that no other company measures. Our first target is ICU medication safety- a much better way to administer essential but powerful sedative drugs to our most vulnerable ICU patients; the old and the young. Today most patients are over-medicated roughly 60% of the time because we have no effective way to measure the level of sedation. Administering sedatives in an optimal manner is proven to reduce length of stay and direct costs by 25% and to reduce 180-day risk of mortality significantly by 10% for tens of millions of intensive care patients. The company has initial sales, 510(k), long-life patents and is raising $800K to complete outcome studies and develop reference accounts.

Dennis Ford, Founder & CEO, Life Science Nation | Mike Baltay, CEO, Brainstem Biometrics | Lucy Parkinson, VP of Investor Research, LSN | Haig Armaghanian, Investor & Advisor, Brainstem Biometrics

Third Prize: PhysioCue

PhysioCue is on a mission to provide superior quality of life through revolutionary and scientifically proven technology to address epidemics of hypertension and migraine headache with noninvasive devices without side effects. Multinational proprietary technologies that specialized in thermoelectric and bio-sensors are empirically supported by renowned medical experts.

Dennis Ford, Founder & CEO, Life Science Nation | Jonathan Leong, CEO, PhysioCue | Lucy Parkinson, VP of Investor Research, LSN

Thank you to all who competed in the RESI Boston Innovation Challenge, and to all the RESI attendees who took part by investing their votes in their favorite competing companies.

Now Offering RESI NYC Early Bird Rates

Check Out the Investor Panel Agenda at RESI NYC

By Lucy Parkinson, VP of Investor Research, LSN

On November 5th, RESI is coming back to New York, and will bring an agenda full of investor discussions and content on key investor constituencies and life science technology verticals.

RESI NYC includes new panels on AI in Healthcare and Funding NYC’s Earliest Stage Companies, plus the return of the expert sessions on Investing in Oncology Innovation and Asia Cross-Border Investors.  RESI will also present panels on our core technology verticals of Early Stage Therapeutics, Medical Devices, Diagnostics, and Digital Health, and on key investor types such as Angels and Family Offices, Seed Funds, Corporate Venture Capital and Big Pharma.  You can view the entire agenda below.  If you’d like to here from experienced investors on these key topics and book face-to-face meetings with investors all day, you can register now.